Talquetamab-related dysgeusia in multiple myeloma compared to BCMA-targeted bispecifics and high-dose melphalan

Background Dysgeusia is a side effect of the anti-GPRC5DxCD3 bispecific antibody talquetamab (TAL), but other myeloma treatments, such as high-dose melphalan (MEL) with autologous stem cell transplantation (ASCT), are also known to alter taste perception in patients with multiple myeloma (MM). This...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Fleischer, Anna (VerfasserIn) , Roll, Magdalena (VerfasserIn) , Frenking, Jan (VerfasserIn) , Panther, Franziska (VerfasserIn) , Gelbrich, Götz (VerfasserIn) , Strunz, Patrick-Pascal (VerfasserIn) , Riedhammer, Christine (VerfasserIn) , Peter, Jessica (VerfasserIn) , Mersi, Julia (VerfasserIn) , Waldschmidt, Johannes (VerfasserIn) , Kortüm, Martin (VerfasserIn) , Einsele, Hermann (VerfasserIn) , Raab, Marc-Steffen (VerfasserIn) , Maatouk, Imad (VerfasserIn) , Rasche, Leo (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: December 2025
In: Cancer medicine
Year: 2025, Jahrgang: 14, Heft: 23, Pages: 1-9
ISSN:2045-7634
DOI:10.1002/cam4.71401
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1002/cam4.71401
Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/cam4.71401
Volltext
Verfasserangaben:Anna Fleischer, Magdalena Roll, Jan H. Frenking, Franziska Panther, Götz Gelbrich, Patrick-Pascal Strunz, Christine Riedhammer, Jessica Peter, Julia Mersi, Johannes Waldschmidt, Martin Kortüm, Hermann Einsele, Marc-S. Raab, Imad Maatouk, Leo Rasche

MARC

LEADER 00000naa a2200000 c 4500
001 1962406644
003 DE-627
005 20260224121552.0
007 cr uuu---uuuuu
008 260224s2025 xx |||||o 00| ||eng c
024 7 |a 10.1002/cam4.71401  |2 doi 
035 |a (DE-627)1962406644 
035 |a (DE-599)KXP1962406644 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Fleischer, Anna  |d 19XX-  |e VerfasserIn  |0 (DE-588)1297260910  |0 (DE-627)1853593842  |4 aut 
245 1 0 |a Talquetamab-related dysgeusia in multiple myeloma compared to BCMA-targeted bispecifics and high-dose melphalan  |c Anna Fleischer, Magdalena Roll, Jan H. Frenking, Franziska Panther, Götz Gelbrich, Patrick-Pascal Strunz, Christine Riedhammer, Jessica Peter, Julia Mersi, Johannes Waldschmidt, Martin Kortüm, Hermann Einsele, Marc-S. Raab, Imad Maatouk, Leo Rasche 
264 1 |c December 2025 
300 |b Illustrationen 
300 |a 9 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Zuerst veröffentlicht: 08. Dezember 2025 
500 |a Gesehen am 24.02.2026 
520 |a Background Dysgeusia is a side effect of the anti-GPRC5DxCD3 bispecific antibody talquetamab (TAL), but other myeloma treatments, such as high-dose melphalan (MEL) with autologous stem cell transplantation (ASCT), are also known to alter taste perception in patients with multiple myeloma (MM). This study investigates the spectrum, prevalence and severity of dysgeusia in patients receiving TAL and MEL and compares the results with anti-BCMA bispecifics as a control for T-cell-engaging therapies. Methods Gustatory and olfactory performance was assessed in 87 MM patients divided into three treatment groups: TAL (n = 26), MEL/ASCT (n = 35), and BCMA bispecifics (n = 26). Evaluations included Taste Strips, Sniffin' Sticks Identification Test 16, and comprehensive questionnaires on taste perception, dietary issues, quality of life (QoL), mood, and treatment compliance. Results TAL-treated patients exhibited severe taste impairment, with 96.2% reporting marked declines. Taste alterations were also observed in patients receiving MEL/ASCT and BCMA bispecifics, though these were less pronounced, affecting 62.9% and 30.8% of cases, respectively. Xerostomia incidence was highest in the TAL group. Patients considering discontinuation of TAL (30%) cited taste alterations as the primary reason. MEL was associated with higher incidences of nausea, vomiting, and appetite loss. Conclusion TAL-associated taste disturbances have a major impact on patients and require further investigation and mitigation strategies. Enhanced patient support, proactive monitoring, and targeted interventions are critical to improving the well-being and adherence of MM patients. 
650 4 |a gustatory dysfunction 
650 4 |a immunotherapy 
650 4 |a oral complications 
650 4 |a quality of life 
650 4 |a taste impairment 
650 4 |a treatment adherence 
700 1 |a Roll, Magdalena  |e VerfasserIn  |4 aut 
700 1 |a Frenking, Jan  |e VerfasserIn  |0 (DE-588)1181399858  |0 (DE-627)1662669607  |4 aut 
700 1 |a Panther, Franziska  |e VerfasserIn  |4 aut 
700 1 |a Gelbrich, Götz  |e VerfasserIn  |4 aut 
700 1 |a Strunz, Patrick-Pascal  |e VerfasserIn  |4 aut 
700 1 |a Riedhammer, Christine  |e VerfasserIn  |4 aut 
700 1 |a Peter, Jessica  |e VerfasserIn  |4 aut 
700 1 |a Mersi, Julia  |e VerfasserIn  |4 aut 
700 1 |a Waldschmidt, Johannes  |e VerfasserIn  |4 aut 
700 1 |a Kortüm, Martin  |e VerfasserIn  |4 aut 
700 1 |a Einsele, Hermann  |e VerfasserIn  |4 aut 
700 1 |a Raab, Marc-Steffen  |d 1973-  |e VerfasserIn  |0 (DE-588)124052460  |0 (DE-627)706520998  |0 (DE-576)293998027  |4 aut 
700 1 |a Maatouk, Imad  |e VerfasserIn  |4 aut 
700 1 |a Rasche, Leo  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Cancer medicine  |d Hoboken, NJ : Wiley, 2012  |g 14(2025), 23 vom: Dez., Artikel-ID e71401, Seite 1-9  |h Online-Ressource  |w (DE-627)71860153X  |w (DE-600)2659751-2  |w (DE-576)366682164  |x 2045-7634  |7 nnas  |a Talquetamab-related dysgeusia in multiple myeloma compared to BCMA-targeted bispecifics and high-dose melphalan 
773 1 8 |g volume:14  |g year:2025  |g number:23  |g month:12  |g elocationid:e71401  |g pages:1-9  |g extent:9  |a Talquetamab-related dysgeusia in multiple myeloma compared to BCMA-targeted bispecifics and high-dose melphalan 
856 4 0 |u https://doi.org/10.1002/cam4.71401  |x Verlag  |x Resolving-System  |z kostenfrei  |3 Volltext  |7 0 
856 4 0 |u https://onlinelibrary.wiley.com/doi/abs/10.1002/cam4.71401  |x Verlag  |z kostenfrei  |3 Volltext  |7 0 
951 |a AR 
992 |a 20260224 
993 |a Article 
994 |a 2025 
998 |g 124052460  |a Raab, Marc-Steffen  |m 124052460:Raab, Marc-Steffen  |d 910000  |d 910100  |e 910000PR124052460  |e 910100PR124052460  |k 0/910000/  |k 1/910000/910100/  |p 13 
998 |g 1181399858  |a Frenking, Jan  |m 1181399858:Frenking, Jan  |d 910000  |d 910100  |e 910000PF1181399858  |e 910100PF1181399858  |k 0/910000/  |k 1/910000/910100/  |p 3 
999 |a KXP-PPN1962406644  |e 4921785015 
BIB |a Y 
SER |a journal 
JSO |a {"language":["eng"],"title":[{"title":"Talquetamab-related dysgeusia in multiple myeloma compared to BCMA-targeted bispecifics and high-dose melphalan","title_sort":"Talquetamab-related dysgeusia in multiple myeloma compared to BCMA-targeted bispecifics and high-dose melphalan"}],"note":["Zuerst veröffentlicht: 08. Dezember 2025","Gesehen am 24.02.2026"],"relHost":[{"language":["eng"],"note":["Gesehen am 07.05.13"],"id":{"eki":["71860153X"],"zdb":["2659751-2"],"issn":["2045-7634"]},"title":[{"title":"Cancer medicine","title_sort":"Cancer medicine"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"pubHistory":["1.2012 -"],"recId":"71860153X","physDesc":[{"extent":"Online-Ressource"}],"part":{"extent":"9","pages":"1-9","year":"2025","volume":"14","text":"14(2025), 23 vom: Dez., Artikel-ID e71401, Seite 1-9","issue":"23"},"disp":"Talquetamab-related dysgeusia in multiple myeloma compared to BCMA-targeted bispecifics and high-dose melphalanCancer medicine","origin":[{"publisherPlace":"Hoboken, NJ","dateIssuedKey":"2012","publisher":"Wiley","dateIssuedDisp":"2012-"}]}],"recId":"1962406644","person":[{"given":"Anna","role":"aut","family":"Fleischer","display":"Fleischer, Anna"},{"given":"Magdalena","role":"aut","family":"Roll","display":"Roll, Magdalena"},{"display":"Frenking, Jan","family":"Frenking","role":"aut","given":"Jan"},{"display":"Panther, Franziska","family":"Panther","role":"aut","given":"Franziska"},{"role":"aut","given":"Götz","display":"Gelbrich, Götz","family":"Gelbrich"},{"role":"aut","given":"Patrick-Pascal","display":"Strunz, Patrick-Pascal","family":"Strunz"},{"display":"Riedhammer, Christine","family":"Riedhammer","role":"aut","given":"Christine"},{"family":"Peter","display":"Peter, Jessica","given":"Jessica","role":"aut"},{"display":"Mersi, Julia","family":"Mersi","role":"aut","given":"Julia"},{"display":"Waldschmidt, Johannes","family":"Waldschmidt","role":"aut","given":"Johannes"},{"display":"Kortüm, Martin","family":"Kortüm","role":"aut","given":"Martin"},{"given":"Hermann","role":"aut","family":"Einsele","display":"Einsele, Hermann"},{"display":"Raab, Marc-Steffen","family":"Raab","role":"aut","given":"Marc-Steffen"},{"role":"aut","given":"Imad","display":"Maatouk, Imad","family":"Maatouk"},{"family":"Rasche","display":"Rasche, Leo","given":"Leo","role":"aut"}],"id":{"doi":["10.1002/cam4.71401"],"eki":["1962406644"]},"name":{"displayForm":["Anna Fleischer, Magdalena Roll, Jan H. Frenking, Franziska Panther, Götz Gelbrich, Patrick-Pascal Strunz, Christine Riedhammer, Jessica Peter, Julia Mersi, Johannes Waldschmidt, Martin Kortüm, Hermann Einsele, Marc-S. Raab, Imad Maatouk, Leo Rasche"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"physDesc":[{"extent":"9 S.","noteIll":"Illustrationen"}],"origin":[{"dateIssuedKey":"2025","dateIssuedDisp":"December 2025"}]} 
SRT |a FLEISCHERATALQUETAMA2025